CTNM · Contineum Therapeutics, Inc. · Executive Compensation
$12.65
-0.07 (-0.55%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$494.34M
Shares
37.62M
Volume · Oct 6
761.92K
Avg daily vol (3M)
501.02K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Carmine N. Stengone | President and Chief Executive Officer | $3,409,448 |
| Timothy R. Watkins | M.D., MSc. Chief Medical Officer and Head of Development | $1,763,323 |
| Peter T. Slover | Chief Financial Officer | $1,577,903 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Carmine N. Stengone | President and Chief Executive Officer | $4,900,039 |
| John S. Healy | General Counsel and Corporate Secretary | $2,562,489 |
| Stephen L. Huhn | Former Chief Medical Officer and Senior Vice President of Clinical Development | $2,121,674 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Carmine N. Stengone | President and Chief Executive Officer | $2,315,299 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Diego Miralles, M.D. | member of its Board | Appointed | 2025-03-17 |
| Sarah Boyce | member of its Board | Appointed | 2024-06-24 |
| Troy Ignelzi | Class I director | Appointed | 2024-05-20 |